Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers in Cell Cover Study

Summary

The paper introduces three interconnected resources for the global scientific community: - LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology; - Longevity-LLMs, a family of compact, open-source language models specifically trained on clinical and multi-omics aging data; and - Longevity Claw, an open-source agentic research platform that autonomously integrates specialized longevity tools to identify and prioritize potential therapeutic targets. CAMBRIDGE, Mass., September 17, 2026 — Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the publication of a landmark study in Cell introducing an open AI toolkit, incluiding LongevityBench, Longevity-LLMs and LongevityClaw designed to accelerate research and therapeutic development in aging and longevity. The study, selected as the cover feature of the journal’s September 17, 2026 issue, was conducted in collaboration with researchers from Liquid AI, the Buck Institute for Research on Aging, and Harvard Medical School and Brigham and Women’s Hospital. The publication follows Insilico’s September 7, 2026 study in Nature Biotechnology, which reported that rentosertib — Insilico’s AI-discovered and AI-designed drug candidate for idiopathic pulmonary fibrosis — reduced biological age across six independent proteomic aging clocks in a Phase IIa clinical trial. Together, the two studies connect clinical evidence from an AI-discovered therapeutic with an open research infrastructure intended to help scientists identify and develop the next generation of longevity interventions. “Insilico is at the forefront of longevity research. Our recent work on rentosertib, published in Nature Biotechnology, demonstrated that an AI-designed drug can modulate biological aging signatures. In our Cell cover paper, we build on this work by empowering the global scientific community with tools such as LongevityBench, Longevity LLM and Longevity Claw, helping transform AI into an autonomous engine for longevity discovery. The longevity community is moving beyond static aging clocks toward foundation models capable of generating measurable, actionable insights. We are developing benchmarked, agentic systems that can evolve into personalized longevity assistants and lo…